The 23 references in paper Yu. Olefir V., V. Merkulov A., E. Soloviev A., E. Ustyugova A., L. Sayapina V., V. Bondarev P., Ю. Олефир В., В. Меркулов А., Е. Соловьев А., Е. Устюгова А., Л. Саяпина В., В. Бондарев П. (2018) “Опыт российского и зарубежного законодательства в области регулирования внесения пострегистрационных изменений в досье на лекарственные препараты // Russian and foreign legislation on regulation of post approval variations in the dossier for the medicinal products” / spz:neicon:vedomostincesmp:y:2015:i:4:p:11-15

1
Frey-Stanislawski Е. Revision of the Variation Regulations Commission Regulation (EC) No. 1084/2003 and No. 1085/2003. Industry-Proposals and Consultation Paper from the European Commission, Impact on Industry and Health Authorities. Master-Thesis, Bonn 2007.
(check this in PDF content)
2
Public Consultation Paper. Better Regulation of Pharmaceuticals: Towards a Simpler, Clearer and More Flexible Framework on Variations. European Commission, October 2007.
(check this in PDF content)
3
Commission Regulation (EC) No 542/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorization falling within the scope of Council Regulation (EEC) No 2309/93.
(check this in PDF content)
4
Commission Regulation (EC) No 1234/2008 of 24 November concerning the examination of variations to the terms of marketing authorizations for medicinal products for human use and veterinary medicinal products. Official Journal of the European Union, L 334/7–24. R E F E R E N C E S Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation, 8 Petrovsky Boulevard, Moscow, 127051, Russian Federation. Olefir YuV. Director General. Doctor of Medical Sciences. Merkulov VA. Deputy Director General for the expertise of drugs. Doctor of Medical Sciences, professor. Soloviev EA. Deputy head of Office of expertise of an tibacterial medical immunobiological preparations of Cen ter of exper
(check this in PDF content)
5
Commission Regulation (EU) No 712/2012 of 3 August 2012 amending Regulation (EU) No 1234/2008 concerning the examination of variations to the terms of marketing authorizations for medicinal products for human use and veterinary medicinal products. Official Journal of the European Union, L 209/4-14.
(check this in PDF content)
6
Guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorizations for medicinal products for human use and veterinary medicinal products and on the documentation to be submitted pursuant to those procedures. European Commission, Brussels, 2013.
(check this in PDF content)
7
Practical questions and answers to support the implementation of the variations guidelines in the centralized procedure. EMA/427505/2013.
(check this in PDF content)
8
European Medicines Agency post-authorization procedural advice for users of the centralized procedure. EMEA-H-19984/03.
(check this in PDF content)
9
Changes to an approved application. Code of Federal regulations, title 21, volume 7, part 601 – licensing, subpart C- biologics licensing, Sec. 601.12.
(check this in PDF content)
10
Supplements and other changes to an approved application. Code of Federal regulations, title 21, volume 5, part 314 – application for FDA approval to market a new drug, subpart B- applications, Sec. 314.70.
(check this in PDF content)
11
Changes to an Approved NDA or NDA. Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), April 2004.
(check this in PDF content)
12
Changes to an Approved Application: Biological Products. Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), July 1997.
(check this in PDF content)
13
Immediate Release Solid Oral Dosage Forms. Scale up and Post-approval Changes: chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation. Guidance for industry, Center for Drug Evaluation and Research (CDER), November 1995.
(check this in PDF content)
14
BACPAC I: Intermediates in drug substances synthesis. Bulk Actives Post Approval Changes: chemistry, manufacturing, and controls documentation. Guidance for industry, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), February 2001.
(check this in PDF content)
15
Changes to an Approved NDA or ANDA Questions and Answers. Guidance for industry, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 2001.
(check this in PDF content)
16
Q8(R2) Pharmaceutical Development. International Conference on Harmonization; 2009.
(check this in PDF content)
17
ICH Q9 Quality Risk management. International Conference on Harmonization; 2006.
(check this in PDF content)
18
ICH Q10 Pharmaceutical Quality System. International Conference on Harmonization; 2008.
(check this in PDF content)
19
ICH Q11 Development and manufacture of drug. International Conference on Harmonization; May 2012.
(check this in PDF content)
20
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Final Concept paper. International Conference on Harmonization; 2014.
(check this in PDF content)
21
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Final Business Plan. International Conference on Harmonization; 2014.
(check this in PDF content)
22
On circulation of medicines. Federal Law No 61-FZ, 12.04.2010 (in Russian).
(check this in PDF content)
23
Bunyatyan ND, Korsun LV, Shprah ZS, Sakanyan VA, Demin MS. Questions of the drug market circulation in the framework of the Custom Union. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2012; (1): 42–45 (in Russian). 5. Commission Regulation (EU) No 712/2012 of 3 August 2012 amending Regu-
(check this in PDF content)